
Husband, Dad, Public Affairs @PhRMA | Fmr Cap Hill - E&C and Fred Upton | CMU & MSU alum
EL | DC
Joined March 2011
- Tweets5.2K
- Following517
- Followers1K
- Likes4.1K
NEW report: The biopharmaceutical industry in America directly employs more than 1 million people & drives $1.74 trillion in economic activity phrma.org/blog/the-1-74-tril…
38
Why 340B needs an itemized bill: phrma.org/blog/why-340b-need…
1
72
She’s a Republican. He’s a Democrat. Married 35 years.
One thing Amye and Charlie Joseph agree on? Frustration with PBMs controlling where they fill prescriptions and what they pay.
Taking on the powerful middlemen standing between patients and their medicines has become a bipartisan cause. Read more here: ow.ly/3AUT50ZVtNH
PhRMA Foundation makes unprecedented investment in America’s future scientific workforce
Learn more: phrma.org/blog/-phrma-founda…
54
As candidates make their case ahead of the midterms, the first-ever Voters for Cures/Morning Consult poll sends a clear message: voters are most concerned about rising health insurance costs.
votersforcures.org/resources…
1
77
Tom Wilbur retweeted
A new report finds hospitals, clinics and their for-profit partners generated $142B in profits from 340B medicine markups in 2025 alone. The evidence is clear: The debate is no longer whether the federal 340B program needs reform, but how to reform it to ensure the program serves the patients it was created to help. Learn more: ow.ly/o8wQ50ZTs4p
New poll shows voters want policymakers to tackle health insurance costs votersforcures.org/resources…
We are excited to announce Eric Cantor as our next president and CEO.
Eric is well respected among policy leaders in Washington and around the world, with a long track record of working effectively across the political spectrum in support of biomedical research and patients’ access to medicines. He joins PhRMA at a pivotal moment for America’s biopharmaceutical industry.
Read more: phrma.org/resources/phrma-se…
Vaccines Remain Our Most Important Public Health Tool votersforcures.org/advocate-…
2
57
ICYMI: Biopharmaceutical companies in America hit new investment milestone phrma.org/blog/icymi-biophar…
62
Nearly 1 in 4 patients initially denied access to IRA medicines phrma.org/blog/nearly-1-in-4…
1
64
Tom Wilbur retweeted
Why is there a whole lot more talk about drug prices than hospital prices?
Paraphrasing bank robber Willie Sutton: If we want to restrain health spending, we have to go where the money is -- hospitals.
@JAMA_current @JAMAHealthForum
jamanetwork.com/journals/jam…
Guest Blog: Price controls won’t lower costs when insurers control access phrma.org/blog/guest-blog-pr…
2
68
. @robzirk in @thehill: Cheaper medicines exist — middlemen are keeping them out of reach thehill.com/opinion/healthca…
1
83
Tom Wilbur retweeted
. @SteveUbl runs @PhRMA, one of the most powerful lobbies in Washington. He joined @BrodyMullinsDC and @camoosomiller on The Deciders to talk gene therapy, pharmacy middlemen, AI, and the innovation race with China. New episode. youtu.be/-ap2B0pBxSg
Staffing up: Building the future biopharma workforce to keep America in the lead phrma.org/blog/staffing-up-b…
1
53
State price-setting boards create more questions than answers phrma.org/blog/state-price-s…
60
Last week, @PhRMA welcomed 76 researchers from 25 member companies to Washington, D.C. for our annual Federal Researcher Fly-in event.
phrma.org/blog/nearly-80-res…
33
Patients speak out: #MFN won't address my affordability concerns phrma.org/blog/patients-spea…
51
As a history buff, I found this absolutely fascinating and well done. Nearly 200 primary sources!
𝐓𝐡𝐞 𝐌𝐨𝐬𝐭 𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 340𝐁 𝐩𝐚𝐩𝐞𝐫 𝐘𝐨𝐮'𝐥𝐥 𝐄𝐯𝐞𝐫 𝐑𝐞𝐚𝐝
If you care about #340B policy, use the long weekend to read this outstanding new paper:
"Stretching Scarce Authorizing Legislation as Far as Possible: A Legislative History of the 340B Drug Pricing Program."
Sayeh Nikpay @saynikpay and her colleagues went back to the early 1990's to reconstruct the program's origins. Their research draws on interviews with 18 key participants and 175 primary source documents spanning 1990–1992.
Their conclusion is difficult to ignore:
340B was originally designed as a narrow policy solution to address an unintended consequence of Medicaid’s best-price provision and to support core safety-net providers.
But the paper makes a compelling case that today’s program extends far beyond Congress’s original intent.
Whether you support or oppose the current structure of 340B, this paper is essential reading for anyone who wants to understand how we got here.
Read it here: drugch.nl/4dVSiTD
One especially fascinating detail: The disproportionate share hospital (DSH) eligibility threshold of 11.75% was chosen to qualify two specific hospitals and secure bipartisan support from Senator Hatch and Representative Bliley.
In other words, the threshold was not grounded in any broader scientific or policy rationale.
Amazing.
1
59







